# Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

> **NCT02283788** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 67 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** BIA 2-093
- **DRUG:** Moxifloxacin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02283788
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02283788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02283788, "Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02283788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*